Medical Communications

Showing 15 posts of 6402 posts found.

Shionogi gains US approval in complicated urinary tract infections with Fetroja

November 15, 2019 Medical Communications, Sales and Marketing FDA, Fetroja, Shiogoni

Shionogi’s antibacterial therapy Fetroja (cefiderocol) has secured approval in the US for the treatment of complicated urinary tract infections (cUTI), …
fda2outsideweb

Label expansion of Amarin’s Vascepa has unanimous backing of FDA advisory panel

November 15, 2019 Medical Communications, Sales and Marketing Amarin, FDA, vascepa

The FDA’s Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) has voted in favour of expanding the existing approval of Irish …
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

November 15, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

As we close in on the weekend, it’s been a week characterised by data reveals and crucial marketing approvals, including …
astrazeneca_sign_sky

AstraZeneca’s Qtrilment scores European authorisation in type 2 diabetes

November 15, 2019 Medical Communications, Sales and Marketing AstraZeneca, EU, Europe, Qtrilmet, diabetes, pharma, type 2 diabetes

Qtrilmet (metformin hydrochloride, saxagliptin and dapagliflozin) has secured approval in Europe, its manufacturer AstraZeneca has revealed, as a therapy to …
diabetes-777001_960_720

New report reveals shocking knowledge gaps around type 2 diabetes risk factors

November 14, 2019 Medical Communications, Research and Development Merck KGaA, diabetes, pharma, type 2 diabetes

A new report released on World Diabetes Day has shone a light on a startling lack of knowledge surrounding type …
sarah_mcdonald

Myeloma UK reveals new Director of Research appointment

November 14, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Myleoma UK, appointment, multiple myeloma, pharma

UK non-profit organisation Myeloma UK has selected Sarah McDonald as its new Director of Research, who in her new role …
white_and_ford

Abbott CEO to step down after 21 years

November 13, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Abbott, appointment

After more than two decades at the head of the company, it has emerged that Miles D White (pictured, right) …
funk

Lonza CEO to step down in 2020

November 12, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Lonza, appointment

It has been announced that Marc Funk, Chief Executive Officer at Lonza, is set to step down from the role …

Working Life Interview: Alison Muir, Oncology Product Strategy Director at Roche

November 11, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Roche, Working Life, feature, pharma

You studied biology at Liverpool John Moores University before heading straight to GSK in 1990 as a Sales Representative; was …
bavencio

Pfizer and Merck KGaA’s Bavencio falls short of primary endpoint in Phase 3 gastric cancer trial

November 8, 2019 Medical Communications, Research and Development Bavencio, Merck KGaA, Pfizer, pharma

Pfizer and Merck KGaA’s EMD Serono have lifted the lid on new Phase 3 data for Bavencio (avelumab) in the …
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

November 8, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

In our rundown of the week’s most popular stories, President Donald Trump has named his first choice for the top …

Roche terminates Duchenne muscular dystrophy candidate due to poor clinical outlook

November 8, 2019 Medical Communications, Research and Development Duchenne Muscular Dystrophy, Roche, pharma

Roche has revealed its decision to terminate further development of its anti-myostatin adnectin protein agent RG6206 after it became apparent …
astrazeneca_sign_sky

AstraZeneca’s roxadustat boosts haemoglobin levels in two Phase 3 trials

November 8, 2019 Medical Communications, Research and Development AstraZeneca, pharma, roxadustat

AstraZeneca’s hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) roxadustat has made a strong showing in the treatment of deficient haemoglobin (Hb) …

Takeda’s Ninlaro shows progression-free survival benefit in multiple myeloma

November 8, 2019 Medical Communications, Research and Development Ninlaro, Takeda, multiple myeloma, pharma

Takeda has revealed strong new findings for Ninlaro (ixazomib), confirming that the therapy met its primary endpoint as a first-line …
paul-campanelli

Endo President and CEO to retire, search for a successor begins

November 7, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Endo pharma, appointment

Endo International has announced its “CEO succession plan”, revealing that the company’s Chief Executive and President Paul V Campanelli has …
The Gateway to Local Adoption Series

Latest content